Proteostasis Therapeutics Inc (PTI) Insider Meenu Chhabra Purchases 40,000 Shares of Stock
Proteostasis Therapeutics Inc (NASDAQ:PTI) insider Meenu Chhabra acquired 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were purchased at an average price of $5.00 per share, with a total value of $200,000.00. Following the completion of the acquisition, the insider now owns 50,218 shares of the company’s stock, valued at approximately $251,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Proteostasis Therapeutics Inc (NASDAQ:PTI) traded up $0.55 during mid-day trading on Wednesday, reaching $5.02. The company’s stock had a trading volume of 2,282,900 shares, compared to its average volume of 366,847. Proteostasis Therapeutics Inc has a 12-month low of $1.41 and a 12-month high of $16.67.
Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. equities research analysts predict that Proteostasis Therapeutics Inc will post -2.47 EPS for the current year.
PTI has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a research note on Tuesday. Zacks Investment Research downgraded Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Leerink Swann raised their price target on Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. Finally, Robert W. Baird raised their price target on Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.